News summaryIFF Investor RelationsNov 3, 2026, 12:00 PM
IFF raises low end of 2026 outlook after Q3 results; adjusted EPS and sales top consensus
earningscorporate_earningsbiotechnology
On Nov. 3, IFF reported Q3 adjusted EPS ex-amortization of $0.83 versus $0.813 consensus and sales of $1.94B versus $1.91B. Comparable currency-neutral sales rose 5% and adjusted EBITDA rose 6%. It raised FY2026 sales guidance to $7.5B–$7.6B from $7.4B–$7.6B and adjusted EBITDA to $1.55B–$1.60B from $1.53B–$1.60B; Q4 profitability expected softer, particularly Health & Biosciences. Shares closed d